**Abbreviations**


[3] Bowtell DD et al. Rethinking ovarian cancer II: Reducing mortality from high-grade

Ubiquitin Signaling in Ovarian Cancer: From Potential to Challenges

http://dx.doi.org/10.5772/intechopen.75485

149

[4] Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: New opportunities for

[6] Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carci-

[7] Perets R, Drapkin R. It's totally tubular….riding the new wave of ovarian cancer research.

[8] Eddie SL et al. Tumorigenesis and peritoneal colonization from fallopian tube epithe-

[9] Kauff ND et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study.

[10] Walerych D et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nature Cell Biology. 2016;**18**(8):897-909

[11] Gallo LH, Ko J, Donoghue DJ. The importance of regulatory ubiquitination in cancer and

[12] Pickart CM. Mechanisms underlying ubiquitination. Annual Review of Biochemistry.

[14] Wu-Baer F et al. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. The Journal

[15] Metzger MB, Hristova VA, Weissman AM. HECT and RING finger families of E3 ubiqui-

[16] Kirkin V, Dikic I. Ubiquitin networks in cancer. Current Opinion in Genetics & Develop-

[17] Wu W et al. The ubiquitin E3 ligase activity of BRCA1 and its biological functions. Cell

[18] Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. Journal

[19] Weberpals JI, Clark-Knowles KV, Vanderhyden BC. Sporadic epithelial ovarian cancer: Clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. Journal

[20] Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or

tin ligases at a glance. Journal of Cell Science. 2012;**125**(Pt 3):531-537

[13] Swatek KN, Komander D. Ubiquitin modifications. Cell Research. 2016;**26**(4):399-422

[5] Cho KR, ShihIe M. Ovarian cancer. Annual Review of Pathology. 2009;**4**:287-313

serous ovarian cancer. Nature Reviews. Cancer. 2015;**15**(11):668-679

translation. Nature Reviews. Cancer. 2009;**9**(6):415-428

noma. Nature. 2011;**474**(7353):609-615

lium. Oncotarget. 2015;**6**(24):20500-20512

metastasis. Cell Cycle. 2017;**16**(7):634-648

2001;**70**:503-533

ment. 2011;**21**(1):21-28

Division. 2008;**3**:1

Journal of Clinical Oncology. 2008;**26**(8):1331-1337

of Biological Chemistry. 2003;**278**(37):34743-34746

of Clinical Oncology. 2005;**23**(21):4776-4789

of Clinical Oncology. 2008;**26**(19):3259-3267

ovarian. MedGenMed. 2005;**7**(2):60

Cancer Research. 2016;**76**(1):10-17
